Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response

Korneliusz Golebski,Janice A Layhadi,Umit Sahiner,Esther H Steveling-Klein,Madison M Lenormand,Rachael C Y Li,Suzanne M Bal,Balthasar A Heesters,Gemma Vilà-Nadal,Oliver Hunewald,Guillem Montamat,Feng Q He,Markus Ollert,Oleksandra Fedina,Mongkol Lao-Araya,Susanne J H Vijverberg,Anke-Hilse Maitland-van der Zee,Cornelis M van Drunen,Wytske J Fokkens,Stephen R Durham,Hergen Spits,Mohamed H Shamji,Janice A. Layhadi,Esther H. Steveling-Klein,Madison M. Lenormand,Rachael C.Y. Li,Suzanne M. Bal,Balthasar A. Heesters,Feng Q. He,Susanne J.H. Vijverberg,Cornelis M. van Drunen,Wytske J. Fokkens,Stephen R. Durham,Mohamed H. Shamji

DOI: https://doi.org/10.1016/j.immuni.2020.12.013

IF: 32.4

2021-02-01

Immunity

Abstract:The role of innate immune cells in allergen immunotherapy that confers immune tolerance to the sensitizing allergen is unclear. Here, we report a role of interleukin-10-producing type 2 innate lymphoid cells (IL-10 ⁺ ILC2s) in modulating grass-pollen allergy. We demonstrate that KLRG1 ⁺ but not KLRG1 ^– ILC2 produced IL-10 upon activation with IL-33 and retinoic acid. These cells attenuated Th responses and maintained epithelial cell integrity. IL-10 ⁺ KLRG1 ⁺ ILC2s were lower in patients with grass-pollen allergy when compared to healthy subjects. In a prospective, double-blind, placebo-controlled trial, we demonstrated that the competence of ILC2 to produce IL-10 was restored in patients who received grass-pollen sublingual immunotherapy. The underpinning mechanisms were associated with the modification of retinol metabolic pathway, cytokine-cytokine receptor interaction, and JAK-STAT signaling pathways in the ILCs. Altogether, our findings underscore the contribution of IL-10 ⁺ ILC2s in the disease-modifying effect by allergen immunotherapy.

immunology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to understand how allergen immunotherapy (AIT) achieves immune tolerance to sensitizing allergens by inducing type 2 innate lymphoid cells (ILC2s) that produce interleukin - 10 (IL - 10). Specifically, the study aims to reveal the role of these regulatory IL - 10+ ILC2s in the immunomodulation and clinical response of allergic diseases.

### Research Background
Seasonal allergic rhinitis (SAR) is an upper respiratory tract disease caused by allergens, affecting up to 30% of adults and 40% of children worldwide. Although drugs such as antihistamines and corticosteroids can provide temporary relief, these drugs are ineffective for some patients. At this time, allergen - specific immunotherapy (AIT) becomes an effective treatment option. AIT can be administered by subcutaneous injection (SCIT) or sublingual administration (SLIT) and can provide long - term clinical benefits after a 3 - year course of treatment.

### Research Questions
1. **The Role of IL - 10+ ILC2s**: Researchers attempt to clarify how IL - 10+ ILC2s play an immunomodulatory role during the AIT process, especially how they restore epithelial cell integrity and inhibit Th2 responses.
2. **Characteristics of IL - 10+ ILC2s**: The phenotypic characteristics of IL - 10+ ILC2s and their differences in healthy individuals and allergic patients are described in detail.
3. **Clinical Relevance**: The relationship between the number of IL - 10+ ILC2s and the efficacy of AIT is explored, and it is found that the symptom severity is negatively correlated with the number of IL - 10+ ILC2s.

### Main Findings
- **Characteristics of KLRG1+ ILC2s**: The study found that only KLRG1+ ILC2s can produce IL - 10 under the stimulation of IL - 33 and retinoic acid (RA), while KLRG1− ILC2s do not have this ability.
- **Functions of IL - 10+ ILC2s**: IL - 10+ ILC2s can not only restore epithelial cell integrity, but also inhibit Th2, Th1 and Th17 cell responses, thereby reducing the inflammatory response.
- **The Effect of AIT**: In patients receiving grass pollen sublingual immunotherapy (SLIT), the number of IL - 10+ ILC2s increased significantly, indicating that AIT can induce the generation of these cells and then improve clinical symptoms.

### Conclusion
This study shows that IL - 10+ ILC2s play a key role in AIT - induced immune tolerance, especially in maintaining epithelial barrier integrity and regulating immune responses. These findings provide a new perspective for understanding the mechanism of AIT and may provide a theoretical basis for future treatment strategies.